Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

AIDS vaccines and adjuvant formulations

C E Cernescu1

  • 1St. Nicolau Institute of Virology, Bucharest, Romania.

International Journal of Immunopharmacology
|May 1, 1994
PubMed
Summary

Preventive AIDS vaccines face challenges, but experimental immunogens and adjuvants show promise. Adjuvant formulations are crucial for overcoming HIV diversity and enhancing immune responses for an effective AIDS vaccine.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dynamics of the HIV-1 variability in adults from Bucharest, 1992-1998.

Romanian journal of virology·2001
Same author

Phagocytic function of monocytes in children with human immunodeficiency virus type 1 infection.

Clinical and diagnostic laboratory immunology·2000
Same author

The serologic significance of F viral genotype for human immunodeficiency virus type 1 epidemic.

The Journal of infectious diseases·1994
See all related articles

Area of Science:

  • Immunology
  • Vaccinology
  • Public Health

Background:

  • The global AIDS epidemic necessitates effective prevention strategies.
  • Current prevention programs require enhancement, particularly vaccine development.
  • HIV's complexity poses significant challenges for vaccine design.

Purpose of the Study:

  • To review promising experimental immunogens for preventive AIDS vaccines.
  • To assess the readiness of these immunogens against optimal vaccine requirements.
  • To explore the role of adjuvants in overcoming specific AIDS vaccine challenges.

Main Methods:

  • Review of experimental immunogens and their potential.
  • Analysis of adjuvant categories: alum, mineral, bacterial, cytokines, carriers, vehicles.
  • Discussion of adjuvant mechanisms and formulation strategies.

Main Results:

  • Adjuvants can address HIV subtype variability, antibody/T-cell responses, mucosal immunity, and serological differentiation.
  • Various adjuvant categories show potential but optimal formulation remains empirical.
  • Advances in immunology clarify adjuvant mechanisms but practical application requires further research.

Conclusions:

  • Adjuvants are critical for developing effective preventive AIDS vaccines.
  • Further research and standardized preclinical testing protocols for adjuvants are a priority.
  • Optimizing adjuvant formulations is key to overcoming HIV's challenges in vaccine development.

Related Experiment Videos